Effect of Addition of Fentanyl or Dexamethasone or Both to Bupivacaine in Paravertebral Block for Patients Undergoing Major Breast Surgery
NCT ID: NCT03480308
Last Updated: 2021-02-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
1 participants
INTERVENTIONAL
2018-04-01
2021-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dexmedetomidine vs Dexamethasone as Adjuvant to Bupivacaine in Bilevel Erector Spinae Plane Block in Breast Surgeries
NCT05591417
Comparing Effect of Adding Ketamine Versus Dexmedetomidine to Bupivacaine in Pec 11 Modified Block on Postoperative Pain Control in Patients Undergoing Breast Surgery
NCT04380168
Dexamedatomidine vs. Dexamethasone in Rhomboidal Intercostal Plain Block and Subserratus Block in Breast Surgery
NCT05385523
Evaluation of the Analgesic Effect of Dexmedetomidine Versus Fentanyl as Adjuvants to Epidural Bupivacaine in Patients Undergoing Lumbar Spine Surgeries
NCT03463083
Effects of Adding Dexamethasone Plus Ketamine to Bupivacine in Serrtatus Plane Block
NCT05775393
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients will receive ultrasound guided paravertebral block and stratified into 3 groups according to medication used :
Group 1 : bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg Group 2 : bupivacaine (0.5%) 20 ml , dexamethasone 4 mg Group 2 : bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg , dexamethasone 4 mg
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
Group 1 : bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg Group 2 : bupivacaine (0.5%) 20 ml , dexamethasone 4 mg Group 2 : bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg , dexamethasone 4 mg
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bupivacaine fentanyl group
Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block
Fentanyl
Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block
Bupivacaine
Bupivacaine
Bupivacaine dexamethasone group
Patients will receive bupivacaine (0.5%) 20 ml , dexamethasone 4 mg in paravertebral block
Dexamethasone
Patients will receive bupivacaine (0.5%) 20 ml , Dexamethasone 4mg in paravertebral block
Bupivacaine
Bupivacaine
Bupivacaine fentanyl dexamethasone group
Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg , dexamethasone 4 mg in paravertebral block
Fentanyl
Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block
Dexamethasone
Patients will receive bupivacaine (0.5%) 20 ml , Dexamethasone 4mg in paravertebral block
Bupivacaine
Bupivacaine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fentanyl
Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block
Dexamethasone
Patients will receive bupivacaine (0.5%) 20 ml , Dexamethasone 4mg in paravertebral block
Bupivacaine
Bupivacaine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Sex: females
* ASA physical status: I-II.
* Operation: major breast surgery
Exclusion Criteria
* History of cardiac disease, psychological disorders, respiratory diseases including asthma, renal or hepatic failure.
* Coagulation disorders.
* Infection at the puncture site
* Allergy to study medications.
* Chronic use of pain medications.
* Respiratory tract in¬fection within the last 2 weeks.
* Neurological deficit
18 Years
70 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amonios khalil
doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amonios khalil
Role: STUDY_DIRECTOR
Faculty of medicine-Assiut university-Egypt
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Amonios Khalil gerges
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
paravertebral block
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.